Genome-wide association studies (GWAS) have been tremendously successful in the field of multiple sclerosis (MS) susceptibility: over the past 10 years, we have gone from having just the HLA DRB1*1501 risk haplotype to having 233 variants which each have an independent effect on disease risk. The latest study includes data from 47,351 subjects with MS and 68,284 control subjects, and the design of its replication phase involved testing all 4842 single-nucleotide polymorphisms (SNPs) which had a p value of <0.05 in the discovery phase. 1 This very thorough design was successful in doubling the number of known susceptibility variants. Given this success and the sample size required to achieve it, asking whether the GWAS era is over is a very reasonable question that has a simple answer: No! GWAS are both feasible and necessary in MS. First, the success of gene discovery efforts in MS-one of the human diseases with the most extensive genetic map available today-and the fact that most reported MS susceptibility loci have been validated illustrate the fact that a GWAS is a very robust study design. When deployed at the proper sample size and with rigorous statistical methods, a GWAS will return results that are definitive and serve as an excellent platform from which to launch further investigations. Thus, a GWAS is a key tool in the modern translational MS scientist's toolbox, one that rests on genotyping platforms costing as little as US$20 per sample and an array of statistical programs that can be readily used. Involvement of a statistical geneticist remains nonetheless "de rigueur" as the ease of completing a GWAS analysis is only matched by the ease with which population history and cryptic confounders can introduce spurious signals of association.
Does our success mean that we have attained a point of diminishing returns in susceptibility studies? With 233 variants to be explored functionally to understand the molecular events that lead to the onset of MS, we certainly have a vast amount of work to be done on each variant, so there is plenty of biology to pursue with current results. However, we know that there are probably a few hundred additional variants that remain to be discovered: just in the latest report, there are 118 strongly suggestive variants. 1 Most of these variants are likely to be truly involved in MS susceptibility. Furthermore, current results are limited by available genotyping technologies which produce excellent data but do have blind spots. There are regions of the human genome that remain unexplored in MS and for which different technologies, such as sequencing, will be needed. Another limitation is the fact that, for practical reasons, GWAS have been performed primarily in subjects of European ancestry; similar efforts in other human populations are ongoing but need to be expanded considerably to be meaningful. 2 A more comprehensive genetic map than the one available today will enhance efforts to understand how susceptibility variants interact with one another to cause alterations in immune responses that lead to MS: one cannot adequately model a network of molecular events leading to disease onset if more than half of its features remain unknown. A more complete census of MS variants also enhances the power of techniques such as "Mendelian randomization" that leverages GWAS results from MS and MS-associated traits such as vitamin D levels to explore the extent to which the genetic architecture of one trait contributes to that of another. 3 This issue of establishing causality is a challenging one that cannot be established in cross-sectional epidemiologic studies. Finally, a comprehensive map is also necessary for developing better predictive models that can identify individuals at very high risk of developing MS among those, like family members, that have an increased risk of MS. A recent report suggests that such a Genetic Risk Score can help to identify a subset of family members who are asymptomatic but may have early evidence of the disease. 4 Beyond larger studies of susceptibility to MS, GWAS can, proportionally, have a bigger impact on our understanding of disease course and treatment response. It is important to highlight that the current PL De Jager large MS GWAS 1 is focused on the relatively simple question of identifying variants whose frequency is altered in individuals with MS when compared to individuals who are "healthy." Many of the latter control subjects are relatively poorly characterized; however, they are appropriate for a susceptibility GWAS since the frequency of MS in the general population (~0.001) is such that minimal statistical power is lost when using population-based control subjects, which reduce the cost of large-scale studies. So far, these susceptibility variants appear to have little or no relevance to the course of the disease, even in the aggregate. 5, 6 Even the strong effects found in the major histocompatibility complex have only very modest effects of measures of brain atrophy. 7 GWAS of treatment response and measures of disability such as those based on the Expanded Disability Status Scale have been performed with limited success and few reproducible results; for example, one SLC9A9 variant has mixed evidence of replication. 8 The lack of clear success in these GWAS is primarily attributable to the lack of robust, quantitative measures of outcome that can drive a well-powered study, to the moderate sample sizes available in academic studies of treatment response, and to the variation in how treatment response is defined in each MS research group. Thus, GWAS offers the promise to uncover genes robustly associated with disease course or treatment response once a well-designed and properly powered study has been executed, which has yet to occur. Since we currently lack a fundamental biological understanding of neurodegeneration in MS, GWAS is a key strategy to identify, in an unbiased but structured manner, genes that will provide a new foundation for elaborating molecular pathways involved in neurodegeneration.
A GWAS strategy can also be deployed in a complementary setting to map the genetic architecture of molecular traits. Mapping the effect of SNPs on gene expression 9 or RNA splicing 10 is the most common approach, but epigenomic, proteomic, or metabolomic measures have also been targeted. These effects are referred to "quantitative trait locus" (QTL) effects; RNA-based studies are called expression QTL or "eQTL" studies. As illustrated by the GTEX resource (https://www.gtexportal.org/home/), these studies provide an important set of reference maps that primarily identify those variants near a given gene that influence the gene's expression (cis-eQTLs). However, one can also perform such GWAS for a single gene of interest, which minimizes the testing burden and yields "trans QTL" effects. This strategy can be very useful in identifying novel regulators of an important gene in an unbiased manner.
Overall, a "GWAS" therefore remains an essential tool for the modern human biologist and clinician-scientist. Backed by robust and cost-effective genotyping as well as mature analytic methods, the GWAS era will continue to return high-quality, robust results, and the utility of this approach to explore very different MS-related questions is only limited by the ingenuity of the investigator. Future GWAS will be most impactful in the study of MS disease course once an appropriate outcome measure is collected systematically in large numbers of MS patients: they will identify genes involved in the neurodegenerative process of MS, which remains poorly understood today. Even in the narrow case of the MS susceptibility GWAS, much more remains to be done to establish the comprehensive genetic map that will enhance molecular and epidemiologic studies and also power the development of predictive algorithms and primary prevention strategies. 11 Thus, there is no doubt that the era of GWAS is NOT over.
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That genome-wide association studies (GWAS) are an effective strategy to identify underlying genetic susceptibility for complex diseases is undisputable. At the time of this writing, 3172 publications have reported 52,491 unique single-nucleotide polymorphism (SNP)-trait associations according to the GWAS Catalog, a database that tracks large, genome-wide studies. With more than 200 genome-wide, replicated associations, multiple sclerosis (MS) is one of the most resounding success stories of the GWAS paradigm. Part of the success of this approach results from the large number of samples studied, which in turn highlights the collaborative, multi-center nature of these studies. However, as a consequence of this, increasingly smaller effects are being detected. Then, the question becomes "when do we stop searching?" Some researchers may argue that GWAS have reached a point of diminishing returns and that it is no longer cost-effective to keep assembling and genotyping larger cohorts (even when the price of genotyping continues to drop on a yearly basis). This point of view is represented here by Koen Vandenbroeck. While this is a plausible argument, it assumes that the only benefit of GWAS is the identification of susceptibility loci. Phil de Jager presents the opposite view and argues that associations with more detailed (endo)phenotypes can be detected by GWAS if these are measured with precision in large, homogeneous cohorts. These phenotypes include severity of disease, response to disease modifying therapies, and quantitative traits of importance to MS such as vitamin D levels, anti-Epstein-barr nuclear antigen (EBNA) titers, or neurofilament concentrations. In addition, GWAS could still be useful in unraveling the genetic architecture of MS in nonEuropean populations where MS is prevalent, such us African Americans, Middle Eastern, and Latino.
As Koen Vandenbroeck points out, GWAS only have the potential to identify association with DNA variants that are common in the population (typically present in at least in 5% of individuals). This strategy would then miss any association with rare variants. However, a recent study in type 2 diabetes with more than 100,000 subjects indicates that variants associated with this disease after sequencing were overwhelmingly common and most fell within regions previously identified by GWAS. 1 Another argument made against more GWAS in MS is that there are already a large number of loci in which to conduct functional studies. Arguably, these studies would provide the ultimate evidence that susceptibility to MS is genetically determined and uncover which cellular pathways are most likely responsible for MS risk. The identification of cellspecific expression quantitative trait loci (eQTL), gene regulatory pathways, and epigenetic mechanisms regulated by the more than 200 MS-associated variants 2 awaits and will undoubtedly brings us closer to understanding genetic risk to MS. At the same time, with some additional data gathering, many of the
